Obicetrapib is advancing as a differentiated CETP inhibitor with robust LDL and HDL effects, supported by strong clinical, genetic, and preclinical data. PREVAIL CVOT is on track, with interim analysis expected in early 2025, and commercial launch preparations are well underway in both the U.S. and Europe.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.